1887
  1. Home
  2. Eurosurveillance
  3. Volume 30, Issue 6, 13/Feb/2025
  4. Article
Rapid communication Open Access
Like 0
Download

  • Infants needed to immunise with nirsevimab to prevent one RSV hospitalisation, Spain, 2023/24 season separator commenting unavailable

  • Roberto Pastor-Barriuso1,2 ORCID icon, Olivier Núñez1,2 , Susana Monge1,3 ORCID icon, the Nirsevimab Effectiveness Study Collaborators4
  • View Affiliations Hide Affiliations
  • The Nirsevimab Effectiveness Study Collaborators: Carmen Olmedo, David Moreno-Perez, Nicola Lorusso, Sergio Fernández Martínez, Pedro Eliseo Pastor Villalba, María Ángeles Gutierrez Rodriguez, Marcos Alonso Garcia, Pello Latasa, Rosa Sancho, Jacobo Mendioroz, Montserrat Martinez-Marcos, Enriqueta Muñoz Platón, María Victoria García Rivera, Olaia Pérez-Martinez, Rosa Álvarez-Gil, Eva Rivas Wagner, Nieves López Gonzalez-Coviella, Matilde Zornoza, M Isabel Barranco, M del Carmen Pacheco, Virginia Álvarez Río, Miguel Fiol Jaume, Roxana Morey Arance, Begoña Adiego Sancho, Manuel Mendez Diaz, Noa Batalla, Cristina Andreu, Jesús Castilla, Manuel García Cenoz, Ana Fernández Ibáñez, Marta Huerta Huerta, Ana Carmen Ibáñez Pérez, Belén Berradre Sáenz, Joaquín Lamas, Luisa Hermoso, Susana Casado Cobo, Manuel Galán Cuesta, Sara Montenegro, María Domínguez, Inmaculada Jarrín, Aurora Limia, Inés del Ramo Torreblanca, Ana Lameiras Azevedo, Irene Morales Arjona, Alejandra López Zambrano, M Dolores Lasheras Carbajo, José Francisco Barbas del Buey, Mª Jesús Rodríguez Recio, Ermengol Coma, Luca Basile, María Ángeles Rafael de la Cruz López, Emma Corraliza Infanzón, María-Isolina Santiago-Pérez, María-Teresa Otero-Barrós, Jaime Jesús Pérez Martín, Alonso Sánchez Migallón, Giselle Pérez Suarez, Leticia Bravo Muñoz, Itziar Casado, Guillermo Ezpeleta, Pilar Alonso Vigil, Mario Margolles, Eva Martínez Ochoa, María Merino Díaz, Julián Manuel Domínguez Fernández, Ninoska Lopez Berrios, María Victoria Jiménez Cabanillas, Daniel Castrillejo, Gorka Loroño Ortiz, Koldo López Guridi, Luis Viloria
    View Citation Hide Citation

    Citation style for this article: Pastor-Barriuso Roberto, Núñez Olivier, Monge Susana, the Nirsevimab Effectiveness Study Collaborators. Infants needed to immunise with nirsevimab to prevent one RSV hospitalisation, Spain, 2023/24 season. Euro Surveill. 2025;30(6):pii=2500040. https://doi.org/10.2807/1560-7917.ES.2025.30.6.2500040 Received: 15 Jan 2025;   Accepted: 07 Feb 2025

Abstract

Using real-life data from Spain between October 2023 and March 2024, the number needed to immunise (NNI) with nirsevimab and the cost to prevent one RSV hospitalisation were estimated at 90 infants (95% CI: 77–108) and 19,700 EUR for catch-up immunisation, and 41 infants (95% CI: 35–50) and 9,000 EUR for at-birth immunisation. By month of birth, NNI and cost were lowest in infants born shortly before the RSV epidemic peak, with impact decreasing gradually for earlier or later births.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2025.30.6.2500040
2025-02-13
2025-02-15
/content/10.2807/1560-7917.ES.2025.30.6.2500040
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/30/6/eurosurv-30-6-1.html?itemId=/content/10.2807/1560-7917.ES.2025.30.6.2500040&mimeType=html&fmt=ahah

References

  1. Ponencia de Programa y Registro de Vacunaciones, Comisión de Salud Pública del Consejo Interterritorial del Sistema Nacional de Salud. Recomendaciones de utilización de nirsevimab para la temporada 2024-2025 en España. [Recommendations for the use of nirsevimab in the 2024-2025 season in Spain]. Madrid; Ministry of Health. [Accessed: 9 Jan 2025]. Spanish. Available from: https://www.sanidad.gob.es/areas/promocionPrevencion/vacunaciones/comoTrabajamos/docs/Nirsevimab.pdf
  2. Núñez O, Olmedo C, Moreno-Pérez D, Lorusso N, Fernández Martínez S, Pastor Villalba PE, et al. Effectiveness of catch-up and at-birth nirsevimab immunisation against RSV hospital admission in the first year of life: a population-based case-control study, Spain, 2023/24 season. Euro Surveill. 2025;30(5):2400596.  https://doi.org/10.2807/1560-7917.ES.2025.30.5.2400596  PMID: 39916606 
  3. Ezpeleta G, Navascués A, Viguria N, Herranz-Aguirre M, Juan Belloc SE, Gimeno Ballester J, et al. Effectiveness of nirsevimab immunoprophylaxis administered at birth to prevent infant hospitalisation for respiratory syncytial virus infection: a population-based cohort study. Vaccines (Basel). 2024;12(4):383.  https://doi.org/10.3390/vaccines12040383  PMID: 38675765 
  4. Wildenbeest JG, Billard MN, Zuurbier RP, Korsten K, Langedijk AC, van de Ven PM, et al. The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study. Lancet Respir Med. 2023;11(4):341-53.  https://doi.org/10.1016/S2213-2600(22)00414-3  PMID: 36372082 
  5. Muller WJ, Madhi SA, Seoane Nuñez B, Baca Cots M, Bosheva M, Dagan R, et al. Nirsevimab for prevention of RSV in term and late-preterm infants. N Engl J Med. 2023;388(16):1533-4.  https://doi.org/10.1056/NEJMc2214773  PMID: 37018470 
  6. Simões EAF, Madhi SA, Muller WJ, Atanasova V, Bosheva M, Cabañas F, et al. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials. Lancet Child Adolesc Health. 2023;7(3):180-9.  https://doi.org/10.1016/S2352-4642(22)00321-2  PMID: 36634694 
  7. Drysdale SB, Cathie K, Flamein F, Knuf M, Collins AM, Hill HC, et al. Nirsevimab for prevention of hospitalizations due to RSV in infants. N Engl J Med. 2023;389(26):2425-35.  https://doi.org/10.1056/NEJMoa2309189  PMID: 38157500 
  8. Bender R, Blettner M. Calculating the "number needed to be exposed" with adjustment for confounding variables in epidemiological studies. J Clin Epidemiol. 2002;55(5):525-30.  https://doi.org/10.1016/S0895-4356(01)00510-8  PMID: 12007557 
  9. Bender R, Kuss O, Hildebrandt M, Gehrmann U. Estimating adjusted NNT measures in logistic regression analysis. Stat Med. 2007;26(30):5586-95.  https://doi.org/10.1002/sim.3061  PMID: 17879268 
  10. Hutton DW, Prosser LA, Rose AM, Mercon K, Ortega-Sanchez IR, Leidner AJ, et al. Cost-effectiveness of nirsevimab for respiratory syncytial virus in infants and young children. Pediatrics. 2024;154(6):e2024066461.  https://doi.org/10.1542/peds.2024-066461  PMID: 39582316 
  11. Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med. 2022;386(9):837-46.  https://doi.org/10.1056/NEJMoa2110275  PMID: 35235726 
  12. Paireau J, Durand C, Raimbault S, Cazaubon J, Mortamet G, Viriot D, et al. Nirsevimab effectiveness against cases of respiratory syncytial virus bronchiolitis hospitalised in paediatric intensive care units in France, September 2023-January 2024. Influenza Other Respir Viruses. 2024;18(6):e13311.  https://doi.org/10.1111/irv.13311  PMID: 38840301 
  13. Salo H, Sakalauskaitè M, Lévy-Bruhl D, Lindstrand A, Valentiner-Branth P, Wichmann O, et al. Prices of paediatric vaccines in European vaccination programmes. Vaccine X. 2023;15:100392.  https://doi.org/10.1016/j.jvacx.2023.100392  PMID: 37779660 
  14. Shoukat A, Abdollahi E, Galvani AP, Halperin SA, Langley JM, Moghadas SM. Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: a simulation study. Lancet Reg Health Am. 2023;28:100629.  https://doi.org/10.1016/j.lana.2023.100629  PMID: 38026446 
  15. Gebretekle GB, Yeung MW, Ximenes R, Cernat A, Simmons AE, Killikelly A, et al. Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of respiratory syncytial virus disease in Canadian infants. Vaccine. 2024;42(21):126164.  https://doi.org/10.1016/j.vaccine.2024.126164  PMID: 39079810 
Infants needed to immunise with nirsevimab to prevent one RSV hospitalisation, Spain, 2023/24 season
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Roberto+Pastor-Barriuso&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Pastor-Barriuso Roberto</a>, <a href="/search?value1=Olivier+N%C3%BA%C3%B1ez&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Núñez Olivier</a>, <a href="/search?value1=Susana+Monge&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Monge Susana</a>, <a href="/search?value1=the+Nirsevimab+Effectiveness+Study+Collaborators&option1=author&noRedirect=true" class="nonDisambigAuthorLink">the Nirsevimab Effectiveness Study Collaborators</a></span>. Infants needed to immunise with nirsevimab to prevent one RSV hospitalisation, Spain, 2023/24 season. <a href="/content/ecdc">Euro Surveill.</a> 2025;30(6):pii=2500040. <a href="https://doi.org/10.2807/1560-7917.ES.2025.30.6.2500040" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2025.30.6.2500040</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 15 Jan 2025;&nbsp;&nbsp; <span class="generated">Accepted</span>: 07 Feb 2025 </span> </p>
/content/10.2807/1560-7917.ES.2025.30.6.2500040
/content/10.2807/1560-7917.ES.2025.30.6.2500040
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error